Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

Cited In for PubMed (Select 16644713)

1.

Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism.

Menzaghi C, Xu M, Salvemini L, De Bonis C, Palladino G, Huang T, Copetti M, Zheng Y, Li Y, Fini G, Hu FB, Bacci S, Qi L, Trischitta V.

Cardiovasc Diabetol. 2014 Sep 10;13:130. doi: 10.1186/s12933-014-0130-y.

2.
3.

Adiponectin gene polymorphisms and susceptibility to atherosclerosis: A meta-analysis.

Mansourian M, Javanmard SH.

J Res Med Sci. 2013 Jul;18(7):611-6. Review.

4.

Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications.

Murea M, Ma L, Freedman BI.

Rev Diabet Stud. 2012 Spring;9(1):6-22. doi: 10.1900/RDS.2012.9.6. Epub 2012 May 10. Review.

5.

Association between polymorphisms in the adiponectin gene and cardiovascular disease: a meta-analysis.

Zhang H, Mo X, Hao Y, Gu D.

BMC Med Genet. 2012 May 28;13:40. doi: 10.1186/1471-2350-13-40.

6.

Association between genetics of diabetes, coronary artery disease, and macrovascular complications: exploring a common ground hypothesis.

Sousa AG, Selvatici L, Krieger JE, Pereira AC.

Rev Diabet Stud. 2011 Summer;8(2):230-44. doi: 10.1900/RDS.2011.8.230. Epub 2011 Aug 10. Review.

7.

Genetic susceptibility to coronary heart disease in type 2 diabetes: 3 independent studies.

Qi L, Parast L, Cai T, Powers C, Gervino EV, Hauser TH, Hu FB, Doria A.

J Am Coll Cardiol. 2011 Dec 13;58(25):2675-82. doi: 10.1016/j.jacc.2011.08.054.

8.

Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer.

Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci E, Stampfer MJ, Ma J.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2618-27. doi: 10.1158/1055-9965.EPI-11-0434. Epub 2011 Sep 29.

9.
10.

Effects of genetic variations in the adiponectin pathway genes on the risk of colorectal cancer in the Chinese population.

He B, Pan Y, Zhang Y, Bao Q, Chen L, Nie Z, Gu L, Xu Y, Wang S.

BMC Med Genet. 2011 Jul 12;12:94. doi: 10.1186/1471-2350-12-94.

11.

Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells.

Boini KM, Zhang C, Xia M, Han WQ, Brimson C, Poklis JL, Li PL.

Biochim Biophys Acta. 2010 Dec;1801(12):1294-304. doi: 10.1016/j.bbalip.2010.09.001. Epub 2010 Sep 19.

12.

Genetics of diabetes complications.

Doria A.

Curr Diab Rep. 2010 Dec;10(6):467-75. doi: 10.1007/s11892-010-0147-x. Review.

13.

The genetics of vascular complications in diabetes mellitus.

Farbstein D, Levy AP.

Cardiol Clin. 2010 Aug;28(3):477-96. doi: 10.1016/j.ccl.2010.04.005. Review.

14.

Adiponectin gene SNP 276G --> T, nutrient intakes, and cardiovascular disease risk in Korean type 2 DM patients.

Yu SY, Ryu HK, Park HJ, Choi YJ, Huh KB, Kim WY.

Nutr Res Pract. 2007 Winter;1(4):363-70. doi: 10.4162/nrp.2007.1.4.363. Epub 2007 Dec 31.

15.

Inflammatory mediators of hepatic steatosis.

Hijona E, Hijona L, Arenas JI, Bujanda L.

Mediators Inflamm. 2010;2010:837419. doi: 10.1155/2010/837419. Epub 2010 Mar 16. Review.

16.

Association of the +45T>G and +276G>T polymorphisms in the adiponectin gene with insulin resistance in nondiabetic Greek women.

Melistas L, Mantzoros CS, Kontogianni M, Antonopoulou S, Ordovas JM, Yiannakouris N.

Eur J Endocrinol. 2009 Dec;161(6):845-52. doi: 10.1530/EJE-09-0492. Epub 2009 Sep 15.

17.

Mendelian randomization in nutritional epidemiology.

Qi L.

Nutr Rev. 2009 Aug;67(8):439-50. doi: 10.1111/j.1753-4887.2009.00218.x. Review.

18.

Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk.

Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, Baron JA, Ahsan H, Mantzoros C, Pasche B.

JAMA. 2008 Oct 1;300(13):1523-31. doi: 10.1001/jama.300.13.1523.

19.

Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk.

Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, Ahsan H, Pasche B, Mantzoros C.

Cancer Res. 2008 May 1;68(9):3178-84. doi: 10.1158/0008-5472.CAN-08-0533.

20.

L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice.

Peterson SJ, Drummond G, Kim DH, Li M, Kruger AL, Ikehara S, Abraham NG.

J Lipid Res. 2008 Aug;49(8):1658-69. doi: 10.1194/jlr.M800046-JLR200. Epub 2008 Apr 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk